Lexicon Posts $11.3M in Third-Quarter Revenue
LXRX sits 46% above its 52-week low of $1.1.
Summary
Lexicon reported third-quarter revenue of $11.3M, down 20% from a year earlier, with EPS of -0.03. That is a modest top line for a company with a roughly $659M market cap, and the headline gives no cash or guidance figures, so the read on the quarter is incomplete. The revenue base has leaned on milestone payments rather than product sales: the company collected a third $10M milestone from Novo Nordisk in 2026, and Q1 2026 was near breakeven largely on a $20M Novo Nordisk payment.
At the time of this announcement, LXRX was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $658.5M. The 52-week trading range was $1.10 to $2.68. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.